Developer docs
API playgroundTry for free, no card

Search company profiles

Xilio Therapeutics

Full company profile

uuid00006hz

Namestring
Xilio Therapeutics
Legal namestring
Xilio Therapeutics, Inc.
Websiteurl
xiliotx.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies intended to be systemically administered but preferentially activated within the tumor microenvironment. Founded in 2016 and headquartered in Waltham, Massachusetts, the company is listed on NASDAQ under the ticker XLO and operates with a headcount of 51-100 employees following a 21% workforce reduction in March 2024. Its therapeutic candidates are built on a proprietary masking technology platform designed to limit the activity of potent immune-engaging molecules (checkpoint inhibitors, cytokines, bispecifics) to tumor tissue, with the goal of widening the therapeutic index relative to systemic counterparts.

The pipeline centers on Vilastobart (XTX101), a masked anti-CTLA-4 antibody in Phase 1 development including a NSCLC dose-expansion cohort; Efarindodekin Alfa (XTX301), a masked IL-12 program licensed to Gilead Sciences; XTX501, a masked IL-2 plus anti-PD-1 bispecific with an IND filing planned for mid-2026; and an early-stage set of masked T cell engagers targeting CLDN18.2 and a PSMA plus STEAP1 dual-antigen construct. Strategic collaborations with Gilead Sciences and AbbVie validate the platform externally and provide capital, with Xilio having achieved an AbbVie development milestone in Q1 2025.

Xilio's business model is pre-commercial: revenue is generated exclusively from licensing fees, milestone payments, and collaboration economics under its Gilead and AbbVie agreements rather than from product sales. 2025 revenue of approximately $43.8M and 2024 revenue of approximately $6.3M reflect this lumpy, partner-driven profile. The company has funded operations through a sequence of capital actions between March 2024 and February 2026 (a $11.3M private placement alongside the Gilead license, a $50.0M public offering in June 2025, $35.8M from Series B warrant exercises in January 2026, and a $40.0M pre-funded warrant offering in February 2026), ending 2025 with approximately $137.5M in cash and a stated runway through the end of 2027. A 1-for-14 reverse stock split executed in March 2026 maintained Nasdaq listing compliance, and market capitalization stood at approximately $49M as of April 2026.

Short descriptiontext

Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies using a proprietary masking platform, with a pipeline spanning masked anti-CTLA-4, IL-12, and T cell engager programs partnered with Gilead and AbbVie.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapies, tumor-activated biologics, masked cytokine therapy, cancer immunotherapy, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage immuno-oncology therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Collaboration Revenue
TypeLicensing Royalties
Description

Xilio generates revenue through licensing agreements with pharmaceutical companies. The company entered into an exclusive license agreement with Gilead Sciences for its tumor-activated IL-12 program and has a collaboration with AbbVie for masked T cell engagers. Revenue includes upfront payments, milestone payments, and potential royalties on future product sales.

ir.xiliotx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Efarindodekin alfa (XTX301)
Description

A masked IL-12 therapy for cancer immunotherapy, currently in Phase 2 clinical trial as monotherapy for advanced solid tumors

xiliotx.com
+3 more records
Core offering1 text field

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to remain inactive in systemic circulation and be selectively activated by tumor-specific proteases within the tumor microenvironment. Its pipeline includes masked cytokines (IL-12, IL-2), a masked anti-CTLA-4 antibody, and masked T cell engagers, with multiple programs partnered with Gilead Sciences and AbbVie. Revenue is generated through licensing, collaboration upfront payments, development milestones, and potential future royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Efarindodekin alfa demonstrated IL-1 pharmacology in patients with advanced solid tumors: pharmacodynamic data from first-in-human Phase 1 study.
+2 more records
Product overview1 text field

Xilio Therapeutics is a clinical-stage biotechnology company developing a pipeline of tumor-selective, masked immuno-oncology therapies. The company's differentiated approach uses proprietary masking technology to design molecules that remain inactive until they reach the tumor microenvironment, where they are activated by tumor-specific proteases. The core portfolio includes: Vilastobart (XTX101), a masked anti-CTLA-4 in Phase 1/2; Efarindodekin Alfa (XTX301), a masked IL-12 licensed to Gilead and in Phase 2; XTX501, a bispecific PD-1/masked IL-2 with IND planned mid-2026; and two masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1 in preclinical development. The company also maintains an Expanded Access Policy for clinical trial enrollment.

Product and service6 records
1Vilastobart (XTX101)
CategoryClinical-stage immuno-oncology candidate (masked antibody)
Description

A masked, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells only when activated in the tumor microenvironment, intended to reduce the systemic toxicity associated with conventional anti-CTLA-4 therapy. Currently in Phase 1/2 clinical trials in combination with atezolizumab for metastatic colorectal cancer.

2Efarindodekin Alfa (XTX301)
CategoryClinical-stage immuno-oncology candidate (masked cytokine)
Description

A masked IL-12 cytokine designed to potently stimulate anti-tumor immunity and reprogram the tumor microenvironment of poorly immunogenic 'cold' tumors towards an inflamed 'hot' state. Licensed exclusively to Gilead Sciences and currently in Phase 2 clinical trials as monotherapy for advanced solid tumors.

3XTX501
CategoryClinical-stage immuno-oncology candidate (masked bispecific)
Description

A bispecific PD-1/masked IL-2 molecule designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. IND submission planned for mid-2026.

4CLDN18.2 Masked T Cell Engager (XTX601)
CategoryPreclinical immuno-oncology candidate (masked T cell engager)
Description

A potential first-in-class masked T cell engager targeting CLDN18.2 expressed in gastrointestinal cancers (gastric, pancreatic, esophageal) and lung cancer. IND submission planned for 2027.

5PSMA+STEAP1 Masked T Cell Engager
CategoryPreclinical immuno-oncology candidate (masked T cell engager)
Description

A potential first-in-class dual-targeted masked T cell engager with built-in co-stimulatory signaling (SEECR format) targeting PSMA and STEAP1 in prostate cancer. Development candidate nomination expected Q2 2026.

6Clinically-Validated Masking Technology Platform
CategoryProprietary immuno-oncology technology platform
Description

Proprietary integrated biology and protein engineering platform for designing masked biologics (cytokines, antibodies, T cell engagers) that remain inactive systemically and are selectively activated by tumor-specific matrix metalloproteases and other proteases within the tumor microenvironment; supports multiple internal programs and external partnerships.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-03-01
Description

Exclusive license agreement with Gilead Sciences for Xilio's tumor-activated IL-12 program, including efarindodekin alfa (XTX301). Xilio received $17.5 million development milestone payment in 2025. Gilead also participated in multiple financing rounds as an investor.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Collaboration on wholly-owned masked T cell engager program. Xilio achieved a development milestone for its masked antibody-based immunotherapy program under the collaboration with AbbVie.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biotech developing INDUKINE conditional-activation cytokine therapeutics. Closest analog to Xilio's masked/conditionally activated biologics platform with overlapping mechanism (protease-activated cytokines).

TypeDirect peer
Description

Clinical-stage biotech using SAFEbody and POWERbody masking technologies to conditionally activate antibodies in the tumor microenvironment. Directly comparable platform-level approach to Xilio's masking technology.

TypeBroad incumbent
Description

Developer of T cell engagers (HPN328, HPN217) acquired by Merck in 2024. Competes in the T cell engager space overlapping with Xilio's masked TCE programs (XTX601, PSMA/STEAP1), but without the masking/conditional activation layer.

TypeDirect peer
Description

Clinical-stage biotech developing masked T cell engager (TRACTr) therapeutics with tumor-selective activation. Directly comparable to Xilio's masked TCE pipeline in mechanism and target indications.

TypeEmerging player
Description

Clinical-stage oncology biotech developing targeted therapies including immune engagers and oncology-focused biologics. Comparable as a similarly sized clinical-stage oncology platform with partnered and wholly-owned assets.

TypeDirect peer
Description

Develops COBRA conditionally active T cell engagers; acquired by Takeda in 2021. Direct mechanistic analog to Xilio's masked/conditionally activated T cell engagers in solid tumors.

7Bristol-Myers Squibb
TypeBroad incumbent
Description

Owns Yervoy (anti-CTLA-4), Opdivo, and a broad I-O franchise that competes directly with Xilio's masked anti-CTLA-4 vilastobart and other I-O candidates. Establishes the benchmark that any new CTLA-4 or PD-1 axis therapy must beat.

TypeBroad incumbent
Description

Owns Keytruda and has acquired Harpoon Therapeutics; competing incumbent in I-O and T cell engagers that Xilio's masked programs must either displace or combine with in clinical practice.

TypeBroad incumbent
Description

Major oncology incumbent with Tecentriq, a broad pipeline of I-O agents and T cell engagers, and significant internal masking/conditional activation research. Competes for the same indications and BD partnerships Xilio targets.

10Surface Oncology (Coherus Biosciences)
TypeEmerging player
Description

Clinical-stage I-O company focused on next-generation immuno-oncology, acquired by Coherus. Comparable as a similarly small, focused I-O pipeline company whose strategic trajectory (acquisition) represents a plausible exit template for Xilio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xilio Therapeutics

Clinical-stage immuno-oncology therapeuticsxiliotx.com

Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies using a proprietary masking platform, with a pipeline spanning masked anti-CTLA-4, IL-12, and T cell engager programs partnered with Gilead and AbbVie.

What Xilio Therapeutics does

Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies intended to be systemically administered but preferentially activated within the tumor microenvironment. Founded in 2016 and headquartered in Waltham, Massachusetts, the company is listed on NASDAQ under the ticker XLO and operates with a headcount of 51-100 employees following a 21% workforce reduction in March 2024. Its therapeutic candidates are built on a proprietary masking technology platform designed to limit the activity of potent immune-engaging molecules (checkpoint inhibitors, cytokines, bispecifics) to tumor tissue, with the goal of widening the therapeutic index relative to systemic counterparts.

The pipeline centers on Vilastobart (XTX101), a masked anti-CTLA-4 antibody in Phase 1 development including a NSCLC dose-expansion cohort; Efarindodekin Alfa (XTX301), a masked IL-12 program licensed to Gilead Sciences; XTX501, a masked IL-2 plus anti-PD-1 bispecific with an IND filing planned for mid-2026; and an early-stage set of masked T cell engagers targeting CLDN18.2 and a PSMA plus STEAP1 dual-antigen construct. Strategic collaborations with Gilead Sciences and AbbVie validate the platform externally and provide capital, with Xilio having achieved an AbbVie development milestone in Q1 2025.

Xilio's business model is pre-commercial: revenue is generated exclusively from licensing fees, milestone payments, and collaboration economics under its Gilead and AbbVie agreements rather than from product sales. 2025 revenue of approximately $43.8M and 2024 revenue of approximately $6.3M reflect this lumpy, partner-driven profile. The company has funded operations through a sequence of capital actions between March 2024 and February 2026 (a $11.3M private placement alongside the Gilead license, a $50.0M public offering in June 2025, $35.8M from Series B warrant exercises in January 2026, and a $40.0M pre-funded warrant offering in February 2026), ending 2025 with approximately $137.5M in cash and a stated runway through the end of 2027. A 1-for-14 reverse stock split executed in March 2026 maintained Nasdaq listing compliance, and market capitalization stood at approximately $49M as of April 2026.

Xilio Therapeutics firmographics

Firmographics
Name
Xilio Therapeutics
Legal name
Xilio Therapeutics, Inc.
Website
https://xiliotx.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies using a proprietary masking platform, with a pipeline spanning masked anti-CTLA-4, IL-12, and T cell engager programs partnered with Gilead and AbbVie.
Ownership category
akta.pro rank

Xilio Therapeutics industry classification

Industry
Product category
Clinical-stage immuno-oncology therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Immuno-oncology therapies
  • Tumor-activated biologics
  • Masked cytokine therapy
  • Cancer immunotherapy
  • Clinical-stage biotechnology

Where Xilio Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Xilio Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Collaboration Revenue: Xilio generates revenue through licensing agreements with pharmaceutical companies. The company entered into an exclusive license agreement with Gilead Sciences for its tumor-activated IL-12 program and has a collaboration with AbbVie for masked T cell engagers. Revenue includes upfront payments, milestone payments, and potential royalties on future product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Xilio Therapeutics product offering

Product offering

Core offering

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to remain inactive in systemic circulation and be selectively activated by tumor-specific proteases within the tumor microenvironment. Its pipeline includes masked cytokines (IL-12, IL-2), a masked anti-CTLA-4 antibody, and masked T cell engagers, with multiple programs partnered with Gilead Sciences and AbbVie. Revenue is generated through licensing, collaboration upfront payments, development milestones, and potential future royalties.

Product overview

Xilio Therapeutics is a clinical-stage biotechnology company developing a pipeline of tumor-selective, masked immuno-oncology therapies. The company's differentiated approach uses proprietary masking technology to design molecules that remain inactive until they reach the tumor microenvironment, where they are activated by tumor-specific proteases. The core portfolio includes: Vilastobart (XTX101), a masked anti-CTLA-4 in Phase 1/2; Efarindodekin Alfa (XTX301), a masked IL-12 licensed to Gilead and in Phase 2; XTX501, a bispecific PD-1/masked IL-2 with IND planned mid-2026; and two masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1 in preclinical development. The company also maintains an Expanded Access Policy for clinical trial enrollment.

Differentiator

Problem solved

Functional benefit

Brands

  • Efarindodekin alfa (XTX301): A masked IL-12 therapy for cancer immunotherapy, currently in Phase 2 clinical trial as monotherapy for advanced solid tumors
  • Vilastobart (XTX101)
  • XTX501
  • Masked T Cell Engagers

Products and services

  • Vilastobart (XTX101) A masked, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells only when activated in the tumor microenvironment, intended to reduce the systemic toxicity associated with conventional anti-CTLA-4 therapy. Currently in Phase 1/2 clinical trials in combination with atezolizumab for metastatic colorectal cancer.
  • Efarindodekin Alfa (XTX301) A masked IL-12 cytokine designed to potently stimulate anti-tumor immunity and reprogram the tumor microenvironment of poorly immunogenic 'cold' tumors towards an inflamed 'hot' state. Licensed exclusively to Gilead Sciences and currently in Phase 2 clinical trials as monotherapy for advanced solid tumors.
  • XTX501 A bispecific PD-1/masked IL-2 molecule designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. IND submission planned for mid-2026.
  • CLDN18.2 Masked T Cell Engager (XTX601) A potential first-in-class masked T cell engager targeting CLDN18.2 expressed in gastrointestinal cancers (gastric, pancreatic, esophageal) and lung cancer. IND submission planned for 2027.
  • PSMA+STEAP1 Masked T Cell Engager A potential first-in-class dual-targeted masked T cell engager with built-in co-stimulatory signaling (SEECR format) targeting PSMA and STEAP1 in prostate cancer. Development candidate nomination expected Q2 2026.
  • Clinically-Validated Masking Technology Platform Proprietary integrated biology and protein engineering platform for designing masked biologics (cytokines, antibodies, T cell engagers) that remain inactive systemically and are selectively activated by tumor-specific matrix metalloproteases and other proteases within the tumor microenvironment; supports multiple internal programs and external partnerships.

Quantifiable outcome

  • Efarindodekin alfa demonstrated IL-1 pharmacology in patients with advanced solid tumors: pharmacodynamic data from first-in-human Phase 1 study.
  • +2 more outcomes

Companies that use Xilio Therapeutics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Xilio Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Xilio Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Gilead SciencescoreOEM/ Whitelabel/ Licensing Partner · 1 March 2024Exclusive license agreement with Gilead Sciences for Xilio's tumor-activated IL-12 program, including efarindodekin alfa (XTX301). Xilio received $17.5 million development milestone payment in 2025. Gilead also participated in multiple financing rounds as an investor.
  • AbbViecoreStrategic or Co-development Partner · 1 March 2024Collaboration on wholly-owned masked T cell engager program. Xilio achieved a development milestone for its masked antibody-based immunotherapy program under the collaboration with AbbVie.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Xilio Therapeutics competitors and assessment

Company assessment

Direct peers

  • Werewolf Therapeutics: Clinical-stage oncology biotech developing INDUKINE conditional-activation cytokine therapeutics. Closest analog to Xilio's masked/conditionally activated biologics platform with overlapping mechanism (protease-activated cytokines).
  • Adagene: Clinical-stage biotech using SAFEbody and POWERbody masking technologies to conditionally activate antibodies in the tumor microenvironment. Directly comparable platform-level approach to Xilio's masking technology.
  • Janux Therapeutics: Clinical-stage biotech developing masked T cell engager (TRACTr) therapeutics with tumor-selective activation. Directly comparable to Xilio's masked TCE pipeline in mechanism and target indications.
  • Maverick Therapeutics: Develops COBRA conditionally active T cell engagers; acquired by Takeda in 2021. Direct mechanistic analog to Xilio's masked/conditionally activated T cell engagers in solid tumors.

Broad incumbents

  • Harpoon Therapeutics: Developer of T cell engagers (HPN328, HPN217) acquired by Merck in 2024. Competes in the T cell engager space overlapping with Xilio's masked TCE programs (XTX601, PSMA/STEAP1), but without the masking/conditional activation layer.
  • Bristol-Myers Squibb: Owns Yervoy (anti-CTLA-4), Opdivo, and a broad I-O franchise that competes directly with Xilio's masked anti-CTLA-4 vilastobart and other I-O candidates. Establishes the benchmark that any new CTLA-4 or PD-1 axis therapy must beat.
  • Merck & Co. Owns Keytruda and has acquired Harpoon Therapeutics; competing incumbent in I-O and T cell engagers that Xilio's masked programs must either displace or combine with in clinical practice.
  • Roche / Genentech: Major oncology incumbent with Tecentriq, a broad pipeline of I-O agents and T cell engagers, and significant internal masking/conditional activation research. Competes for the same indications and BD partnerships Xilio targets.

Emerging players

  • Cullinan Oncology: Clinical-stage oncology biotech developing targeted therapies including immune engagers and oncology-focused biologics. Comparable as a similarly sized clinical-stage oncology platform with partnered and wholly-owned assets.
  • Surface Oncology (Coherus Biosciences): Clinical-stage I-O company focused on next-generation immuno-oncology, acquired by Coherus. Comparable as a similarly small, focused I-O pipeline company whose strategic trajectory (acquisition) represents a plausible exit template for Xilio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Xilio Therapeutics social profiles

Digital presence

Xilio Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xilio Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Xilio Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xilio Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xilio Therapeutics

What does Xilio Therapeutics do?

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to remain inactive in systemic circulation and be selectively activated by tumor-specific proteases within the tumor microenvironment. Its pipeline includes masked cytokines (IL-12, IL-2), a masked anti-CTLA-4 antibody, and masked T cell engagers, with multiple programs partnered with Gilead Sciences and AbbVie. Revenue is generated through licensing, collaboration upfront payments, development milestones, and potential future royalties.

Is Xilio Therapeutics a public or private company?

Xilio Therapeutics is a public company. It is classified as public and is currently operating.

When was Xilio Therapeutics founded?

Xilio Therapeutics was founded in 2016. It employs 51 to 100 people.

Where is Xilio Therapeutics based?

Xilio Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Xilio Therapeutics make money?

One revenue line is on record: licensing and Collaboration Revenue.

Who are Xilio Therapeutics's main competitors?

Direct peers on record are Werewolf Therapeutics, Adagene, Janux Therapeutics and Maverick Therapeutics. Broad incumbents are Harpoon Therapeutics, Bristol-Myers Squibb, Merck & Co. and Roche / Genentech. Emerging players are Cullinan Oncology and Surface Oncology (Coherus Biosciences).

Does Xilio Therapeutics have an API?

No public API is recorded for Xilio Therapeutics.

What industry is Xilio Therapeutics in?

Xilio Therapeutics's product category is Clinical-stage immuno-oncology therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comXilio Therapeutics at Stifel 2026 Healthcare Conference: pipeline gainsXilio Therapeutics presented its masked immunotherapy platform at the Stifel 2026 Healthcare Conference, with four programs in human testing and two active partnerships. Its lead asset XTX501 entered Phase 1 dose-escalation in post-PD-L1 lung cancer, with efficacy data expected in Q4 2027. The company said cash covers operations through Q1 2028, with up to $140 million in additional capital possible.Quiver QuantitativeXilio Reports $10.0 Million Third-Quarter Revenue and $5.9 Million Net Loss | XLO Stock NewsXilio Therapeutics reported Q3 2026 collaboration and license revenue of $10.0 million and a net loss of $5.9 million, or $0.30 per share. The company dosed the first patient in its Phase 1/2 trial of XTX501 for metastatic non-small cell lung cancer and plans to report initial Phase 1 data in Q4 2027.GlobeNewswireXilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesXilio Therapeutics reported Q3 2026 financial results and pipeline progress, including dosing the first patient in the Phase 1/2 trial for XTX501. The company plans to report initial Phase 1 data in Q4 2027 and submit INDs for XTX602 and XTX701 in Q4 2027. Cash and cash equivalents were $122.2 million as of September 30, 2026.American Banking and Market NewsXilio Therapeutics (NASDAQ:XLO) & Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Critical SurveyXilio Therapeutics and Valion Bio are compared on 13 factors, with Xilio winning 10. Xilio has a stronger analyst consensus, higher institutional ownership, and a lower price-to-earnings ratio. Its consensus price target of $16.00 implies an 85.61% upside.American Banking and Market NewsXilio Therapeutics (XLO) Projected to Announce Quarterly Earnings on ThursdayXilio Therapeutics is expected to report Q3 2026 earnings on Thursday, November 12th, with analysts projecting a loss of $0.9350 per share and revenue of $4.92 million. The company's stock opened at $8.71, and analysts have a consensus "Hold" rating with a $16.00 price target.Stock TitanXilio Therapeutics to Present at Stifel Conference Nov. 10Xilio Therapeutics management will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 2:40 p.m. ET. The company, a clinical-stage biotech developing masked immuno-oncology therapies, will provide a live webcast with a 30-day replay.MarketBeatXilio Therapeutics (NASDAQ:XLO) Stock Rating Upgraded by Zacks ResearchZacks Research upgraded Xilio Therapeutics to a Hold rating, while other firms gave mixed ratings. The company reported Q2 EPS of -$0.33, beating estimates of -$0.59, with revenue of $18.69 million. Institutional investors own 54.29% of the stock.American Banking and Market NewsRaymond James Financial Begins Coverage on Xilio Therapeutics (NASDAQ:XLO)Raymond James Financial began coverage on Xilio Therapeutics with an outperform rating and a $16 price target, implying 99.25% upside. The stock opened at $8.03, and the company reported Q2 EPS of -$0.33, beating estimates of -$0.59, with revenue of $18.69 million.MarketBeatXilio Therapeutics (NASDAQ:XLO) Now Covered by Analysts at Raymond James FinancialRaymond James Financial began coverage of Xilio Therapeutics with an outperform rating and a $16 price target, implying 87.35% upside. The stock opened at $8.54, and the company reported Q2 EPS of -$0.33, beating the -$0.59 consensus, with revenue of $18.69 million versus $12.72 million expected.Investing.comRaymond James initiates Xilio Therapeutics stock with outperform ratingRaymond James initiated coverage on Xilio Therapeutics with an Outperform rating and a $16 price target, citing the company's masking technology in clinical programs. The stock trades at $8.54, with a consensus target of $20 and a fair value of $10.28. The firm noted Xilio's cash position and collaboration opportunities, though its pipeline faced developmental hurdles.